GlassScriptPhysician profile
Jeffrey W David
NPI 1881738870
$3,497.42
in general payments reported to CMS, 2019-2025
36 companies · $648 in 2025
The $648 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $127 · 2022: $564 · 2023: $851 · 2024: $1,015 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.07 | 2019-2024 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Astellas Pharma US INC | $433.24 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $271.63 | 2019-2025 | Evenity, Prolia, Prolia |
| Sage Therapeutics, LLC | $259.64 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $223.59 | 2022-2025 | |
| Exeltis, USA INC. | $201.54 | 2022-2024 | Slynd |
| Organon LLC | $200.16 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $169.88 | 2023-2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $160.31 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.80 | 2019-2025 | |
| Shield Therapeutics INC | $129.04 | 2023-2024 | Accrufer |
| Cumberland Pharmaceuticals, INC. | $79.32 | 2019-2025 | Caldolor |
| Millicent US INC | $74.67 | 2025 | Femlyv, Intrarosa |
| Supernus Pharmaceuticals, INC. | $69.33 | 2025 | Qelbree |
| Exact Sciences Corporation | $59.76 | 2024-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $53.11 | 2022 | |
| Boston Scientific Corporation | $52.70 | 2024 | |
| Smith+Nephew, INC. | $42.30 | 2022-2024 | Pico 7, Pico |
| Vertex Pharmaceuticals Incorporated | $39.59 | 2024-2025 | |
| Allergan, INC. | $39.23 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $33.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.25 | 2019-2020 | |
| Therapeuticsmd, INC. | $29.79 | 2019-2022 | |
| Ethicon US, LLC | $23.07 | 2024 | Stratafix |
| Duchesnay USA Incorporated | $20.70 | 2019 | |
| Evofem Biosciences, INC. | $20.45 | 2022 | |
| Coopersurgical, INC. | $18.14 | 2023 | Paragard T 380a |
| Abbott Laboratories | $17.04 | 2023 | Freestyle Libre 3 |
| Vertical Pharmaceuticals, LLC | $16.85 | 2020 | |
| Myovant Sciences INC. | $16.27 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.16 | 2024 | Exparel |
| Mission Pharmacal Company | $16.01 | 2020 | |
| Conmed Corporation | $15.90 | 2024 | Airseal |
| Molnlycke Health Care US, LLC | $15.40 | 2023 | Mepilex Border Post-Op Ag |
| Dexcom, INC. | $14.53 | 2024 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.